Angel Biotechnology Holdings (ABH 0.1825p / £3.8m)

 Angel, the contract manufacturer, providing extremely high grade materials for the biotechnology industry, has announced another contract win with the large Russian pharma, Materia Medica.

 Whilst this contract for £330,000 isn’t a huge contract compared to the size of previous Materia Medica wins (regularly over £1m) it is for regulatory consultancy. This follows on from the first signing in January for this type of work. It is validation of expertise Angel have, not only in supplying the advanced biologics but also in the complex regulatory procedures involved with these materials and the ability of the team to assist their clients throughout the whole process. The consultancy work relates to the regulatory process connected to specific antibodies that Angel is delivering to Materia Medica.

 This Company is now well funded since it’s placing in February, with the cash available for expansion and clear demonstration of it’s ability to keep pulling in contracts. It is surely an anomaly that the share price continues at these depressed levels, and a fantastic opportunity for investors to top up their holdings.

Autoclenz (ACZ 42.5p / £4.42m)

Autoclenz, the UK's leading provider of outsourced vehicle valeting and specialist cleaning services, gave an update at its AGM that the group is trading in line with budget. Autoclenz expects to at least maintain last year’s level of profitability of £1.4m. The Automotive Services division is recovering, with sales and profitability slightly ahead of budget and the previous year for the first four months to April 2010. The React Specialist Cleaning Services division saw revenues decline by 25 per cent in the same period. The group is reducing the cost base to reflect the decline in revenues but the group has continued to win new contracts although and there are major contracts up for renewal in Q4 2010. With an inevitable squeeze on both public and private expenditure, Autoclenz cannot of course be immune to any new deterioration in economic circumstances. Assuming earnings for 2010 remain flat at 12.5p, the group trades on a P/E ratio of 3.6x, a discount to the support services sector median of 7.4x so giving buyers the chance to clean up at these levels.

Corin Group (LON:CRG) (CRG 57.5p / £24.60m)

Leading manufacturer and supplier of orthopaedic devices last week published an interim management statement for the period from 1…

Unlock the rest of this article with a 14 day trial

Already have an account?
Login here